SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...

Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

SAN ANTONIO -- Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation ...

An experimental vaccine targeting aggressive triple-negative breast cancer (TNBC) has shown encouraging early results in ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or ...

A new study provides more evidence that many patients with early-stage breast cancer may avoid sentinel lymph node surgery ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

Patients with stage I or II hormone receptor-negative breast cancer do not benefit from preoperative breast MRI, according to ...

Stress affects many systems in our body and biologists Marcel Schaaf and Erin Faught at Radboud University are figuring out ...